Rhea-AI Summary
Conexeu Sciences (Nasdaq: CNXU) launched a preclinical development program for its B.R.E.A.S.T.™ 3D-printed bioregenerative breast matrix at the Wake Forest Institute for Regenerative Medicine (WFIRM).
The program will use WFIRM’s bioprinting infrastructure to study durability, host tissue integration and resorbability, guiding future clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
-
Rhea-AI Summary
Conexeu Sciences (Nasdaq: CNXU), a biotechnology company focused on tissue regeneration, has commenced trading on the Nasdaq under ticker CNXU.
The company reports 25,269,996 issued and outstanding shares and 35,238,222 fully diluted shares, and is advancing its proprietary CXU™ regenerative tissue platform and B.R.E.A.S.T.™ 3D-bioprinted breast matrix.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of Conexeu Sciences (CNXU)?
Conexeu Sciences (CNXU) last closed at $3.06.
What is the market cap of Conexeu Sciences (CNXU)?
The market cap of Conexeu Sciences (CNXU) is approximately $86.3M.